Raphaël Szalat

3.5k total citations
64 papers, 954 citations indexed

About

Raphaël Szalat is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Raphaël Szalat has authored 64 papers receiving a total of 954 indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Hematology, 39 papers in Molecular Biology and 14 papers in Oncology. Recurrent topics in Raphaël Szalat's work include Multiple Myeloma Research and Treatments (40 papers), Protein Degradation and Inhibitors (16 papers) and Amyloidosis: Diagnosis, Treatment, Outcomes (11 papers). Raphaël Szalat is often cited by papers focused on Multiple Myeloma Research and Treatments (40 papers), Protein Degradation and Inhibitors (16 papers) and Amyloidosis: Diagnosis, Treatment, Outcomes (11 papers). Raphaël Szalat collaborates with scholars based in United States, France and Italy. Raphaël Szalat's co-authors include Nikhil Munshi, Hervé Avet‐Loiseau, Nikhil C. Munshi, Mehmet Samur, Marion Malphettes, Bouchra Asli, Kenneth C. Anderson, Lionel Galicier, Mariateresa Fulciniti and Bertrand Arnulf and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Blood.

In The Last Decade

Raphaël Szalat

54 papers receiving 942 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Raphaël Szalat United States 19 499 397 267 157 101 64 954
Stéphanie Harel France 15 316 0.6× 315 0.8× 190 0.7× 276 1.8× 112 1.1× 51 785
Zeba N. Singh United States 15 360 0.7× 497 1.3× 485 1.8× 130 0.8× 127 1.3× 54 984
Prajwal Boddu United States 21 373 0.7× 734 1.8× 371 1.4× 361 2.3× 99 1.0× 51 1.2k
Víctor H. Jiménez‐Zepeda Canada 20 914 1.8× 728 1.8× 588 2.2× 272 1.7× 72 0.7× 102 1.3k
Teruaki Hongo Japan 20 478 1.0× 419 1.1× 258 1.0× 165 1.1× 52 0.5× 58 1.2k
Nikolaos Kanellias Greece 21 710 1.4× 819 2.1× 579 2.2× 214 1.4× 75 0.7× 132 1.3k
M. Testi Italy 19 289 0.6× 183 0.5× 244 0.9× 166 1.1× 167 1.7× 62 983
André Baruchel France 22 516 1.0× 757 1.9× 306 1.1× 195 1.2× 199 2.0× 45 1.7k
Neil Rabin United Kingdom 16 396 0.8× 409 1.0× 321 1.2× 195 1.2× 47 0.5× 72 788
Blythe Thomson United States 15 596 1.2× 538 1.4× 329 1.2× 193 1.2× 164 1.6× 39 1.7k

Countries citing papers authored by Raphaël Szalat

Since Specialization
Citations

This map shows the geographic impact of Raphaël Szalat's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Raphaël Szalat with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Raphaël Szalat more than expected).

Fields of papers citing papers by Raphaël Szalat

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Raphaël Szalat. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Raphaël Szalat. The network helps show where Raphaël Szalat may publish in the future.

Co-authorship network of co-authors of Raphaël Szalat

This figure shows the co-authorship network connecting the top 25 collaborators of Raphaël Szalat. A scholar is included among the top collaborators of Raphaël Szalat based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Raphaël Szalat. Raphaël Szalat is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Samur, Anıl Aktaş, Jill Corre, Srikanth Talluri, et al.. (2025). Genomically Smoldering Multiple Myeloma Is Not a Distinct Entity But a Collection of Monoclonal Gammopathy of Undetermined Significance or Multiple Myeloma. Journal of Clinical Oncology. 44(4). 321–334.
2.
Kataria, Yachana, et al.. (2024). Body size and risk of multiple myeloma in the Black Women’s Health Study. British Journal of Cancer. 130(5). 830–835. 1 indexed citations
3.
Szalat, Raphaël, Kenneth Anderson, & Nikhil C. Munshi. (2024). Role of minimal residual disease assessment in multiple myeloma. Haematologica. 109(7). 2049–2059. 11 indexed citations
4.
Abdallah, Maya, Adam Lerner, Fabio Petrocca, et al.. (2024). Febrile neutropenia in patients with Duffy-null–associated neutrophil counts and multiple myeloma or AL amyloidosis. Blood Advances. 8(23). 5935–5938. 1 indexed citations
5.
Teodorescu, Patric, et al.. (2024). Clinical Characteristics and Treatment Outcomes of Patients with AL Amyloidosis with Acquired Factor X Deficiency. Blood. 144(Supplement 1). 4671–4671.
6.
Samur, Mehmet, Marco Roncador, Anıl Aktaş Samur, et al.. (2023). High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma. Blood. 141(14). 1724–1736. 22 indexed citations
7.
Staron, Andrew, Eric Burks, Raphaël Szalat, & Vaishali Sanchorawala. (2023). Prospective Evaluation of Measurable Residual Disease (MRD) and Sustainability of the Response in Patients with Systemic AL Amyloidosis Treated with Daratumumab. Blood. 142(Supplement 1). 3405–3405. 1 indexed citations
8.
Samur, Mehmet, Ricardo Sánchez, Santiago Barrio, et al.. (2021). Pathogenetic and Prognostic Implications of Increased Mitochondrial Content in Multiple Myeloma. Cancers. 13(13). 3189–3189. 5 indexed citations
9.
Szalat, Raphaël, et al.. (2021). Genetic Predictors of Mortality in Patients with Multiple Myeloma. The Application of Clinical Genetics. Volume 14. 241–254. 10 indexed citations
10.
Fillmore, Nathanael R., Jennifer La, Raphaël Szalat, et al.. (2020). Prevalence and Outcome of COVID-19 Infection in Cancer Patients: A National Veterans Affairs Study. JNCI Journal of the National Cancer Institute. 113(6). 691–698. 68 indexed citations
11.
Alagpulinsa, David A., Raphaël Szalat, Mark C. Poznansky, & Robert J. Shmookler Reis. (2020). Genomic Instability in Multiple Myeloma. Trends in cancer. 6(10). 858–873. 23 indexed citations
12.
Samur, Mehmet, Anıl Aktaş Samur, Mariateresa Fulciniti, et al.. (2020). Genome-Wide Somatic Alterations in Multiple Myeloma Reveal a Superior Outcome Group. Journal of Clinical Oncology. 38(27). 3107–3118. 38 indexed citations
13.
Alagpulinsa, David A., Subodh Kumar, Srikanth Talluri, et al.. (2019). Amplification and overexpression of E2 ubiquitin conjugase UBE2T promotes homologous recombination in multiple myeloma. Blood Advances. 3(23). 3968–3972. 12 indexed citations
14.
Szalat, Raphaël, Matija Dreze, Mathew R. Schnorenberg, et al.. (2019). Functional profiling of nucleotide Excision repair in breast cancer. DNA repair. 82. 102697–102697. 8 indexed citations
15.
Perini, Tommaso, Raphaël Szalat, Mariateresa Fulciniti, et al.. (2017). Bone Marrow Microenvironment Induces Genomic Instability and Enables Clonal Evolution in Multiple Myeloma. Blood. 130. 4408. 1 indexed citations
16.
Cleynen, Alice, Raphaël Szalat, Mehmet Samur, et al.. (2017). Expressed fusion gene landscape and its impact in multiple myeloma. Nature Communications. 8(1). 1893–1893. 25 indexed citations
17.
Szalat, Raphaël & Nikhil Munshi. (2017). Diagnosis of Castleman Disease. Hematology/Oncology Clinics of North America. 32(1). 53–64. 29 indexed citations
18.
Szalat, Raphaël, Mehmet Samur, Mariateresa Fulciniti, et al.. (2017). Nucleotide excision repair is a potential therapeutic target in multiple myeloma. Leukemia. 32(1). 111–119. 43 indexed citations
19.
Cohen, Camille, Bruno Royer, Vincent Javaugue, et al.. (2015). Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease. Kidney International. 88(5). 1135–1143. 79 indexed citations
20.
Szalat, Raphaël & Nikhil Munshi. (2015). Genomic heterogeneity in multiple myeloma. Current Opinion in Genetics & Development. 30. 56–65. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Stéphanie Harel Breakdown of academic impact, for papers by Zeba N. Singh Breakdown of academic impact, for papers by Prajwal Boddu Breakdown of academic impact, for papers by Víctor H. Jiménez‐Zepeda Breakdown of academic impact, for papers by Teruaki Hongo Breakdown of academic impact, for papers by Nikolaos Kanellias Breakdown of academic impact, for papers by M. Testi Breakdown of academic impact, for papers by André Baruchel Breakdown of academic impact, for papers by Neil Rabin Breakdown of academic impact, for papers by Blythe Thomson
Rankless by CCL
2026